Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
Lancet 372(9652):18091818 Lee SM et al (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
10.1016/j.ijcard.2007.06.013
In a head-to-head comparison trial pitting ALCAR against carnitine, only ALCAR reduced several biomarkers of oxidative stress within the brain, including those for lipid peroxidation, DNA oxidation, and protein oxidation [21]
New recommendations include specific drug classes for some patients and enhancing medication adherence Following a review of the latest evidence including a range of recent trials of drug and lifestyle interventions the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have produced an updated consensus statement on how to manage hyperglycaemia (high blood sugar) in patients with type 2 diabetes
US$ 21.29
US$ 22.56
US$ 21.85
:max_bytes(150000):strip_icc()/Health-GettyImages-2112991930-7aba42b37c8641d3a76cb03100b26dda.jpg)
